Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM9161 for generalized myasthenia gravis
ChiCTR2100050903Phase 3Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing HBM9161 with Placebo (2 arms). Primary endpoint: Myasthenia Gravis Activities of Daily Living score. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2100050903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050903.